Health and Healthcare
Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week
Published:
Last Updated:
Earnings reporting season for the second quarter is now well underway. So far, things are looking good. The biotech industry has yet to see any significant earnings representation. That will change this week when at least eight large biopharma firms are scheduled to report second-quarter earnings and revenues.
24/7 Wall St. has put together a preview of some of the larger health care companies that are about to report their quarterly results. We have reviewed the consensus earnings estimates from Thomson Reuters, the stock price and trading history.
Be advised that the earnings and revenue estimates may change ahead of the formal reports, and some companies may change earnings dates as well.
Biogen Inc.’s (NASDAQ: BIIB) second-quarter report is scheduled for Tuesday before the markets open. The consensus estimates are $5.24 in earnings per share (EPS) on $3.26 billion in revenue. The shares ended the week trading at $357.56. The consensus price target is $367.08, and the 52-week trading range is $249.17 to $370.57.
Eli Lilly and Co. (NYSE: LLY) is set to release its most recent quarterly results first thing on Tuesday as well. The consensus forecast calls for $1.30 in EPS and $6.05 billion in revenue for the second quarter. Shares traded on Friday’s close at $88.71. The consensus price target is $92.59, and the 52-week range is $73.69 to $89.37.
Gilead Sciences Inc. (NASDAQ: GILD) will report its most recent quarterly results Wednesday afternoon. The consensus estimates for the second quarter call for EPS of $1.56 and $5.2 billion in revenue. The shares were last seen trading at $76.98, in a 52-week range of $64.27 to $89.54. The consensus price target is $86.00.
The Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) second-quarter report is scheduled for Thursday before the opening bell. The consensus forecast is $1.70 in EPS on $977.89 million in revenue. Shares ended the week at $135.27 apiece. The consensus price target is $158.89, and the 52-week range is $102.10 to $149.34.
24/7 Wall St.Amgen Inc. (NASDAQ: AMGN) is expected to release its most recent quarterly results on Thursday. The consensus forecast calls for $3.54 in EPS and $5.74 billion in revenue for the second quarter. Shares traded on Friday’s close at $190.60. The consensus price target is $196.10, and the 52-week range is $163.31 to $201.23.
Bristol-Myers Squibb Co. (NYSE: BMY) will report its most recent quarterly results Thursday morning. The consensus estimates for the second quarter call for EPS of $0.88 and $5.44 billion in revenue. The shares were last seen trading at $56.77, in a 52-week range of $49.96 to $70.05. The consensus price target is $57.56.
Celgene Corp.’s (NASDAQ: CELG) second-quarter report is scheduled for Thursday before the opening bell. The consensus forecast is $2.10 in EPS on $3.7 billion in revenue. Shares ended the week at $85.12 apiece. The consensus price target is $112.65, and the 52-week range is $74.13 to $147.17.
On Friday, AbbVie Inc. (NYSE: ABBV) is scheduled to reveal its second-quarter results. The consensus estimates are $1.97 in EPS and $8.21 billion in revenue. Shares were trading at $88.14 as the week came to a close. The consensus price target is $113.05. The 52-week range is $69.38 to $125.86.
There will be much more to see this week on the earnings front. Also check out our separate previews for Dow components, top tech leaders and other major companies expected to share their latest quarterly results in the coming days.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
